Like R N, Purwanto A P, Dian W


Hemostasis disorders in End Stage Renal Disease (ESRD) might be due to uremia syndrome which causing platelet dysfunction. This condition was worsened by chronic hemodialysis which affected the biologic compound degranulation of thrombogenic β-thromboglobulin causing morphological changes of platelets which could be evaluated by using the value of Platelet Large Cell Ratio (P-LCR) and triggering fibrinolysis hyperactivation which increased the Fibrin Degradation Products (FDP) level. The sequence of this mechanism happened continuously. The platelet index evaluation could decide the prognosis after hemodialysis, in addition to monitoring creatinine levels. This study aimed to prove the difference between P-LCR, β-thromboglobulin level, FDP level and creatinine level between pre and post-hemodialysis. The design of this study was observational analytical. Forty-five samples were examined by complete blood count examination using flowcytometry method, the level of β-TG examination by ELISA method, the level of FDP examination by the immunoturbidimetric method and the level of creatinine examination by enzymatic method. The statistical analysis used the Wilcoxon test. It was found that  the value of P-LCR in ESRD pre-hemodialysis was higher than in post-hemodialysis with the median 26.8 fl and 25.4 fl, the β- thromboglobulin level increased inpost-hemodialysis compared to pre-hemodialysis (median 200.88 pg/mL and 313.48pg/mL), the FDP level was higher in  post-hemodialysis compared to pre-hemodialysis, (median 1.15 µg/mL and 1.7µg/mL), the creatinine level was lower in   post-hemodialysis compared to pre-hemodialysis, (median 13.04 mg/dL and 4.56 mg/dL). Therefore, the statistical value was p<0.01. There were significant differences in P-LCR-value, β-thromboglobulin level, fibrin degradation products level and creatinine level between pre and post-hemodialysis.



P-LCR, β-thromboglobulin, fibrin degradation products, hemodialysis

Full Text:



Thomas R, Kanso A, Sedor JR. chronic kidney disease and its complications. Primary Care. 2008; 35(2): 327-9.

Ulusoy G. Bleeding diathesis in hemodialysis patients. Urology and nephrology. Hemodialysis, 2013; 59-80.

Bladel V. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrology, 2012;13:1-6. Available at

Schoorl M. Platelet morphology and IPF during treatment with hemodialysis. Diagnostic Perspectives, 2011; 1: 28–35.

Ghoshal K. Overview of platelet physiology: Its hemostatic and non-hemostatic role in disease pathogenesis. Scientific World Journal, 2014; 1-16.

Marianne S, Menso JN, Bartels. Coagulation activation, depletion of platelet granules and endothelial integrity in case of uraemia and haemodialysis treatment, BMC Nephrology, 2013; 14:1-7.

Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Seminars in dialysis, 2006; 19: 317-22.

Mitsuhiro K, Shizuko T, Hideto M, Tomohiro M, Shigeki M. Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol, 2002; 22: 329-34.

Anonym. Operator’s manual automated hematology analyzer Sysmex Xn-series. Japan. Sysmex Corporation, 2010.

Anonym. P-LCR Parameter – Platelet Large Cell Ratio 2009. Available at

Babu E, Basu D. Platelet large cell ratio in the differential diagnosis of abnormal platelet count. Indian J Pathol Microbiol, 2004; 47(2): 202-5.

Esther R, Bladel V, Daisy W, Cornelissen L, Carlo AG, Leonie AB, et al. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrology, 2012; 13: 127.

Imam B. Coagulopathy in infection. The proceeding book of the 7th continuing professional development on clinical pathology and laboratory medicine Joglosemar. 2015; 1: 57-9.

Rahajuningsih DS, Silman E. Patofisiologi DIC dan fibrinolisis. Hemostasis dan trombosis 2009; 1: 110-21.

Małyszko J, Buczko W. Hemostasis in chronic renal failure. Annales Academiae Medicae Bialostocensis, 2005; 50: 126-31.

Mörtberg J, Blombȁnk M, Wallȅn Ȃ, He S, Jacobson SH, Spaak J. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease, Blood Coagulation & Fibrinolysis, 2016; 27(4): 401-7.

utz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Hemostasis in chronic kidney disease. Nephrology, dialysis, transplantation. European Dialysis and Transplant Association. Eur Ren Association. 2014; 29: 29-40.

Vagdatli E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: A simple, practical and specific marker of activation of coagulation. Hippokratia, 2010; 14: 28-32.

Amar RS, Menka HS. Role of platelet parameters in diagnosing various clinical conditions. National Journal of Medical Research June, 2013; 3: 162-5.

Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: Does it exist? American Journal of Hematology, 2002; 70(2): 139-44.

Emadaldeen I, Amira AK. Evaluation of D-dimer concentration in pre-hemodialysis in Sudanese patients. BMJ Research, 2016; 2(3): 16-9.

Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney international supplements, 2015; 5(1): 2-7.

Suwitra K. Penyakit ginjal kronik, in: Aru W, Sudoyo, editor, Buku ajar ilmu penyakit dalam, Jilid 2, Ed 5., Jakarta, Interna Publising, 2009; 1: 1035-40.

Noor A, Javaid A, Mudassar Z, Mehmood AR. Evaluating urea and creatinine levels in chronic renal failure pre and post dialysis: A prospective study. J Cardiovascular Disease, 2014; 2(2): 1-4.

Alviani V. Pemeriksaan kadar kreatinin menggunakan alat fotometer dan automated chemistry analyzer pada pasien gagal ginjal di RSUD Ciamis Tahun 2016. 2016: 6-9. cited :



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.